Repligen Corporation (NASDAQ:RGEN – Get Free Report) shares dropped 6.3% during mid-day trading on Tuesday . The company traded as low as $169.41 and last traded at $169.6550. 460,096 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 1,014,037 shares. The stock had previously closed at $180.98.
Analyst Ratings Changes
Several analysts recently commented on the company. Wells Fargo & Company boosted their price target on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Royal Bank Of Canada began coverage on Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Barclays boosted their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Wolfe Research assumed coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. Finally, Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 13th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $166.43.
View Our Latest Stock Report on RGEN
Repligen Stock Performance
Repligen (NASDAQ:RGEN – Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period in the prior year, the business posted $0.26 earnings per share. Repligen’s revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts anticipate that Repligen Corporation will post 2.06 EPS for the current year.
Insider Buying and Selling at Repligen
In other news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.60% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Repligen
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGEN. ABS Investment Management LLC bought a new stake in shares of Repligen in the 2nd quarter valued at about $191,016,000. Measured Wealth Private Client Group LLC bought a new position in Repligen during the 3rd quarter worth approximately $29,000. Los Angeles Capital Management LLC acquired a new position in Repligen during the fourth quarter valued at approximately $36,000. Farther Finance Advisors LLC grew its holdings in Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares during the period. Finally, Itau Unibanco Holding S.A. grew its holdings in Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 104 shares during the period. Institutional investors own 97.64% of the company’s stock.
About Repligen
Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.
Further Reading
- Five stocks we like better than Repligen
- MongoDB’s Spending Fears Collide With a Much Stronger Growth Story
- With the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?
- Could IonQ Become More Than a Quantum Computing Company?
- Why China’s Memory Chip Breakthrough Won’t Crash the Market
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
